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Abstract
Purpose
18F-Fluorodeoxyglucose positron emission tomog-
raphy (FDG PET) has been used to assess metabolic
response several months after stereotactic body radiotherapy
(SBRT) for early-stage non-small cell lung cancer. However,
whether a metabolic response can be observed already during
treatment andthuscanbeusedtopredicttreatmentoutcome is
undetermined.
Methods Ten medically inoperable patients with FDG PET-
positivelung tumours wereincluded. SBRTconsisted of three
fractions of 20 Gy delivered at the 80% isodose at days 1, 6
and 11. FDG PET was performed before, on day 6
immediately prior to administration of the second fraction of
SBRT and 12 weeks after completion of SBRT. Tumour
metabolism was assessed semi-quantitatively using the
maximum standardized uptake value (SUVmax)a n dS U V 70%.
Results After the first fraction, median SUVmax increased
from 6.7 to 8.1 (p=0.07) and median SUV70% increased
from 5.7 to 7.1 (p=0.05). At 12 weeks, both median SUVmax
and median SUV70% decreased by 63% to 3.1 (p=0.008)and
to 2.5 (p=0.008), respectively.
Conclusion SUVincreased during treatment, possibly due to
radiation-induced inflammation. Therefore, it is unlikely that
18F-FDG PET during SBRT will predict treatment success.
Keywords SBRT.Lung tumours.Response monitoring.
FDG PET
Introduction
Lobectomy is considered the treatment of choice for stage I
lung tumours [1]. Until recently, conventionally fractionat-
ed radiotherapy was offered to medically inoperable
patients. Unfortunately, retrospective data suggest poor
overall survival rates for stage I disease treated with
radiotherapy, even with the use of modern 3-D conformal
radiotherapy [2]. Stereotactic body radiotherapy (SBRT) is
a relatively new approach in the treatment of lung tumours,
utilizing stereotactic targeting and precise radiation delivery.
SBRT facilitates hypofractionation with markedly increased
biological equivalent doses (>100 Gy) and reduced overall
treatment times. Numerous trials have now been published
using SBRT for stage I lung tumours. Results are excellent,
with local control rates above 80% at 1–5y e a r s[ 3],
comparable to those obtained with surgery. As a consequence,
SBRT is gradually replacing conventionally fractionated
radiotherapy for non-surgical patients.
18F-Fluorodeoxyglucose positron emission tomography
(FDG PET) imaging, visualizing enhanced glucose utiliza-
tion by tumours, has proven to be useful as a predictive and
prognostic test in various treatment settings including
response assessment during (chemo-) radiotherapy. Also after
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after treatment [4–6]. Being able to predict the outcome after
SBRT in terms of complete tumour response already during
treatment would yield two significant advantages: (1) the
indication for SBRT could safely be extended to include
operable patients, because the few patients who will fail after
SBRT could be offered immediate salvage surgery and (2)
follow-up after SBRT for all patients could be tailored
according to the risk of failure. Both options are very
appealing in order to increase the efficiency of early lung
cancer treatment as well as follow-up.
We performed this pilot study to explore the potential of
FDG PETwith regard to early assessment of tumour response
during SBRT in patients with FDG PET-positive lung
tumours.
Materials and methods
Study design
Medically inoperable patients with an FDG PET-positive
lesioninthelungwithoutFDGuptakeelsewherewereeligible
(stage I lung cancer, according to the UICC TNM Classifica-
tion of Malignant Tumours, 7th edition, 2009). Diagnostic
work-up included bronchoscopy with bronchoalveolar lavage
and biopsy, CT scan and lung function testing. Due to the
small sizes and peripheral location of the target lesions,
cytological and histological confirmation could not be
obtained in any of the patients. Only one patient was regarded
as having sufficient pulmonary reserve to undergo transtho-
racic biopsy, which resulted in pneumothorax without
histological confirmation of the diagnosis. Patients had to
have a WHO performance score of 0–2 and a life expectancy
of at least 6 months. SBRT was delivered using a Novalis®
system (BrainLAB AG, Feldkirchen, Germany), according to
the protocol of the Department of Radiation Oncology at the
University Medical Center Groningen. Briefly, after acquisi-
tion of a planning 4-D CT scan incorporating breathing
motions, the target volume was delineated. Patients received
3 × 20 Gy at the 80% isodose level at days 1, 6 and 11,
respectively. All patients underwent a routine
18F-FDG PET
scan and CT scan 12 weeks after completion of SBRT for
response evaluation. An additional
18F-FDG PET scan to
assess early tumour response was performed at day 6,
immediately before delivery of the second fraction. The
study was approved by the local Medical Ethics Committee
and all patients gave written informed consent prior to
treatment.
Each
18F-FDG PET scan was made at the Department of
Nuclear Medicine and Molecular Imaging on a Siemens/
CTI ECAT EXACT HR+ machine, using the Dutch
Standard Operating Procedures (SOP) for
18F-FDG PET
whole-body scans [7]. In short, patients received FDG at a
dose of 5 MBq per kilogram body weight intravenously.
After a waiting period of 60 min, a scan was made from the
mid-thigh to the external acoustic meatus.
Data analysis and statistics
Datawereassessedvisuallyandsemi-quantitatively,usingthe
maximum standardized uptake values (SUVmax) and the
SUV70% (i.e. the mean SUVin the volume encompassing the
isocontour of 70% of maximum activity). For SUV
calculation, the tumour was delineated using standard
Siemens e.soft analysis and viewing software in order to
eliminate inter-observer variability. In order to render the
SUVs on the three time points comparable, the waiting time
between injection and scanning differed no more than 5 min
among the three examinations, as defined in the SOP [7].
SUVs were corrected for the blood glucose levels (normal-
ization to 5.0 mmol/l). SUVs are expressed as medians
with range. Comparisons between the
18F-FDG PET
scans at different time points were performed using the
Wilcoxon signed rank test. The Mann-Whitney U test was
used to compare groups of different metabolic responders.
Additionally, metabolic response was assessed according
to European Organization for Research and Treatment of
Cancer (EORTC) criteria [8]( s e eT a b l e1). Routine CT
thorax 12 weeks after completion of SBRT was used to
assess tumour response according to Response Evaluation
Criteria in Solid Tumors (RECIST) criteria version 1.1 [9].
Results
Patient characteristics
Ten patients were enrolled between February 2008 and
January 2009 as planned. There were nine men and one
woman with a median age of 77.5 years and a median
Charlson comorbidity index of 4 (range 3–11). Tumour
stage according to the 7th edition of the UICC TNM
Table 1 Definition of metabolic response according to EORTC
criteria
Response Definition
CMR Complete resolution of FDG uptake in tumour, not
distinguishable from surrounding tissue
PMR Reduction of more than 25% in SUV
SMD Changes of less than 25% in SUV
PMD Increase of SUV of more than 25% or new (metastatic)
lesions
CMR complete metabolic response, PMR partial metabolic response,
SMD stable metabolic disease, PMD progressive metabolic disease
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(n=3) and T2a (n=1). The staging
18F-FDG PET scan was
made 5.3 weeks (median; range 3–14 weeks) prior to the
start of SBRT. All patients underwent an
18F-FDG PET
scan on day 6. Routine
18F-FDG PET and CT scans were
performed 12.9 weeks (median; range 11.7–18 weeks) after
completion of SBRT for response evaluation. One patient
refused the
18F-FDG PET at 12 weeks due to increasing
claustrophobia, yielding nine fully evaluable patients.
Patient characteristics are shown in Table 2.
Metabolic and radiological response
Prior to SBRT, median SUVmax was 6.7 (range 4.1–24.8)
and median SUV70% was 5.7 (range 3.4–20.0). After the
first fraction, median SUVmax increased to 8.1 (p=0.07)
(Fig. 1) and median SUV70% increased to 7.1 (p=0.05),
representing a relative increase of 18 and 21%, respectively.
At 12 weeks, a metabolic response was observed in all
evaluable patients (n=9). Four patients showed a complete
metabolic response (CMR) (44%) and five patients showed
a partial metabolic response (56%). Both SUVmax and
SUV70% decreased significantly by 63% (p=0.008) to 3.1
and 2.5, respectively. CMR was not associated with gross
tumour volume (GTV) (p=0.29) or SUVmax prior to
treatment (p=0.34). Routine CT thorax performed 12 weeks
after SBRT showed a partial response in eight patients
(80%) and stable disease in two patients (20%). Sequential
PET/CT images of patient 3 are presented in Fig. 2.
Discussion
SBRT has demonstrated excellent local control rates in
medically inoperable patients, establishing an important
role for definitive SBRT in the treatment of stage I lung
Table 2 Patient characteristics
Patient Sex Age Charlson
index
cTNM GTV
(cm
3)
SUVmax
(before)
SUVmax
(during)
SUVmax
(12 weeks)
Metabolic
response
(12 weeks)
Radiological
response
(12 weeks)
1 M 78 11 T1a N0 M0 5.27 7.1 7.8 3.1 PMR PR
2 F 88 4 T1b N0 M0 7.10 16.4 13.1 1.4 CMR PR
3 M 71 4 T1a N0 M0 4.16 4.1 5.3 1.7 CMR PR
4 M 61 3 T1a N0 M0 2.74 6.3 8.3 1.7 CMR PR
5 M 81 4 T1a N0 M0 5.87 9.0 14.5 NA NA PR
6 M 77 5 T2a N0 M0 16.71 24.8 32.2 3.5 PMR PR
7 M 81 3 T1b N0 M0 1.32 14.6 15.5 3.5 PMR SD
8 M 64 4 T1a N0 M0 0.90 4.3 4.3 1.6 CMR PR
9 M 85 5 T1b N0 M0 9.55 4.3 5.2 3.2 PMR SD
10 M 61 4 T1a N0 M0 2.89 5.0 5.4 3.2 PMR PR
GTV gross tumour volume, CMR complete metabolic response, PMR partial metabolic response, SMD stable metabolic disease, PMD progressive
metabolic disease, PR partial response, SD stable disease
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Fig. 1 Absolute SUVmax
before, after the first fraction
and 12 weeks after completion
of SBRT. SUVmax increased
after the first fraction (p=0.07)
and decreased significantly
12 weeks after SBRT (p=0.008)
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rable to those obtained with surgery, it could be argued that
primary SBRT might also be offered to operable patients as
an alternative to lobectomy. This hypothesis is the basis for
the phase II RTOG 0618 trial and two randomized phase III
trials, i.e. the Dutch ROSEL trial [10] and the STARS trial
[11], both comparing SBRT with surgery. As operable
patients receiving SBRT would remain eligible for potential
salvage surgery in the case of tumour failure, early prediction
of local control already during treatment is tempting since
salvage surgery could then be performed without the need
to complete SBRT and subsequent 3-monthly follow-up
response monitoring.
In our study, the
18F-FDG PET scan preceding the
second of three fractions of SBRT showed an increased
18F-FDG uptake in the tumour. A number of explanations
may exist for this phenomenon. First, the interval between
the staging
18F-FDG PET scan and the start of SBRT varied
widely. Tumour progression may have occurred in between
and may be responsible for the increased uptake. However,
no correlation between SUV changes after the first fraction
and the interval between the staging FDG PET and start of
SBRT was found, suggesting that tumour progression did
not play a major role (data not shown). Another explanation
may be that
18F-FDG PET also detects inflammation [12];
thus, the elevated FDG uptake may be explained by
radiation-induced inflammation with influx of macro-
phages, which are known to exhibit increased
18F-FDG
uptake [13]. Indeed, increased
18F-FDG uptake has been
observed during radiotherapy in patients [6, 14, 15] as well
Fig. 2 Sequential axial PET (upper row), CT (middle row) and fused
PET/CT (lower row) images of patient 3, before (a), after the first
fraction (b) and 12 weeks after SBRT (c). SUVmax increased from 6.3
to 8.3 after the first fraction. At 12 weeks SUVmax decreased to 1.3
(CMR) and was considered a partial response according to RECIST
criteria
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kinetic analysis [17] or dual time point imaging [18, 19]
may have been more accurate for the discrimination
between tumour activity and radiation-induced inflamma-
tion. Also, the use of other tracers capable of discriminating
inflammation from tumour activity, such as proliferation
markers, may be promising and needs further investiga-
tion. Finally, despite inclusion in the Dutch recommenda-
tions, the practice of correcting for plasma glucose is
controversial and certainly not widely used [7]. If we would
have used the uncorrected data, the increase observed after
the first fraction would have been 6% for SUVmax and 9%
for SUV70%. The reduced SUVs at 12 weeks would remain
unchanged, i.e. 63%.
In our institution, follow-up of lung cancer patients
treated with SBRT consists of an
18F-FDG PET/CT scan at
12 weeks, followed by yearly CT scans of the thorax. It
must be kept in mind that the response assessment at
12 weeks is not the standard of care. Its results should be
interpreted with caution, especially since a substantial
proportion of patients may have persistently elevated SUV
up to 1 year after treatment without developing local
recurrence [6]. Secondly, 12 weeks is too early to elicit a
radiological response and longer intervals are needed to
observe tumour shrinkage or disappearance.
In conclusion, given the expectation of at least 80%
local control after SBRT, it is unlikely that
18F-FDG PET
during SBRT will predict treatment success. Advanced
scanning techniques or the use of innovative PET tracers
are needed for early response assessment during hypo-
fractionated high-dose radiotherapy techniques such as
SBRT.
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